|
Ms. Upham is CEO of CureDM, Inc. and has 22 years experience in product and business development for the biotechnology and pharmaceutical industries. Prior to founding CureDM, Ms. Upham was a key member of the licensing and development team for Prolexys Pharmaceuticals, Inc., a Utah based biotechnology company dedicated to mapping human protein interactions. Her role included conducting in-licensing and research collaboration negotiations with strategic partners, including pharmaceutical companies, other biotechnology companies, research institutes, and universities. Before Prolexys, Ms. Upham was the Product and Marketing Manager for Packard BioScience Corporation as well as scientific consultant to their sales force. She was responsible for the global launch and marketing of imaging systems, high throughput screening systems and reagents, including forecasting, training and product support. Ms. Upham started her career as a molecular genetics researcher with Eli Lilly and Company, where she was part of a team that cloned and expressed human proteins, including insulin and growth factors. Ms. Upham holds a BA in Biology from the University of Penn and an MBA in Business from Arizona State University. She currently is a member of the Society for Biomolecular Screening, Licensing Executive Society, and National Association of Female Executives. | 